New pill could slow Parkinson's progression in early stages
Disease control
Completed
This study tested an experimental drug called IkT-148009 (risvodetinib) in 137 people with early, untreated Parkinson's disease. Participants took one of three doses or a placebo daily for 12 weeks. The goal was to check safety and see if the drug improves movement and daily livi…
Phase: PHASE2 • Sponsor: ABLi Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC